Cargando…

Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity

Treatment with an agonist anti-OX40 antibody (aOX40) boosts anti-tumor immunity by providing costimulation and driving effector T cell responses. However, tumor-induced immune suppression contributes significantly to poor response rates to aOX40 therapy, thus combining aOX40 with other agents that r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sturgill, Elizabeth R., Rolig, Annah S., Linch, Stefanie N., Mick, Courtney, Kasiewicz, Melissa J., Sun, Zhaoyu, Traber, Peter G., Shlevin, Harold, Redmond, William L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927986/ https://www.ncbi.nlm.nih.gov/pubmed/33717655 http://dx.doi.org/10.1080/2162402X.2021.1892265

Ejemplares similares

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
por: Curti, Brendan D, et al.
Publicado: (2021)

The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment
por: Farhad, Mohammad, et al.
Publicado: (2018)

Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity
por: Redmond, William L, et al.
Publicado: (2013)

Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer
por: Linch, Stefanie N, et al.
Publicado: (2013)

Galectin-3 inhibition using novel inhibitor GR-MD-02 improves survival and immune function while reducing tumor vasculature
por: Linch, Stefanie, et al.
Publicado: (2015)

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice
por: Linch, Stefanie, et al.
Publicado: (2015)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
por: Redmond, William L., et al.
Publicado: (2023)

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy
por: Friedman, David J, et al.
Publicado: (2014)

Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression
por: Redmond, William L., et al.
Publicado: (2012)

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8(+) T cell responses capable of curing multi-focal cancer
por: Walker, Joshua M, et al.
Publicado: (2020)

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
por: Linch, Stefanie N., et al.
Publicado: (2015)

Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts
por: Linch, Stefanie N, et al.
Publicado: (2014)

A twist in the tail
por: Guillemin, Karen, et al.
Publicado: (2014)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors
por: Scherwitzl, Iris, et al.
Publicado: (2020)

Reprogramming T-Cell Metabolism for Better Anti-Tumor Immunity
por: Ping, Yu, et al.
Publicado: (2022)

Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure
por: Laderach, Diego José, et al.
Publicado: (2021)

Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8(+) T cells
por: McNamara, Michael J, et al.
Publicado: (2014)

Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors
por: Veschi, V, et al.
Publicado: (2014)

Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response
por: Dabi, Yosef Tsegaye, et al.
Publicado: (2022)

PARP-inhibition reprograms macrophages toward an anti-tumor phenotype
por: Wang, Lin, et al.
Publicado: (2022)

Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models
por: Pieper, Alexander A., et al.
Publicado: (2021)

Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity
por: Zheng, Shuang, et al.
Publicado: (2023)

Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy
por: Lee, Yu-Hung, et al.
Publicado: (2021)

Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity
por: Flint, Thomas R., et al.
Publicado: (2016)

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8(+) T cell cytotoxicity over BEMPEG+RT
por: Rolig, Annah S, et al.
Publicado: (2022)

Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8(+) T cells
por: Redmond, William L., et al.
Publicado: (2016)

Perspectives on Reprograming Cancer-Associated Dendritic Cells for Anti-Tumor Therapies
por: Benencia, Fabian, et al.
Publicado: (2014)

Galectin-9 Expression Predicts Favorable Clinical Outcome in Solid Tumors: A Systematic Review and Meta-Analysis
por: Zhou, Xiaoxiang, et al.
Publicado: (2018)

Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors
por: Traber, Peter G., et al.
Publicado: (2013)

Regulation of A1 by OX40 Contributes to CD8(+) T Cell Survival and Anti-Tumor Activity
por: Lei, Fengyang, et al.
Publicado: (2013)

Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing
por: Alves, Eric, et al.
Publicado: (2021)

Hæmatoma—Recurrent Tumor in the Ox
por: Nariman,
Publicado: (1890)

Lipoarabinomannan Decreases Galectin-9 Expression and Tumor Necrosis Factor Pathway in Macrophages Favoring Mycobacterium tuberculosis Intracellular Growth
por: Chávez-Galán, Leslie, et al.
Publicado: (2017)

Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity
por: Vallejo-Ardila, Dora L., et al.
Publicado: (2018)

USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer
por: Dai, Xiaomeng, et al.
Publicado: (2020)

Reduced tumor growth in EP2 knockout mice is related to signaling pathways favoring an increased local anti-tumor immunity in the tumor stroma
por: Khan, Maria, et al.
Publicado: (2022)

Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity
por: Zheng, Yue, et al.
Publicado: (2023)

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
por: Kvarnhammar, Anne Månsson, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ajoldjge1fm810h35cvobnpf1d